Patents Represented by Attorney Brian J. Walsh
-
Patent number: 8333968Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.Type: GrantFiled: February 22, 2011Date of Patent: December 18, 2012Assignee: ZymoGenetics, Inc.Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, George Robert Mabry, III, Stephen R. Jaspers, Monica J. Huber
-
Patent number: 8309692Abstract: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytor17, are located on chromosome 5, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.Type: GrantFiled: April 20, 2011Date of Patent: November 13, 2012Assignee: ZymoGenetics, Inc.Inventors: Cindy A. Sprecher, Scott R. Presnell, Zeren Gao, Theodore E. Whitmore, Joseph L. Kuijper, Mark F. Maurer
-
Patent number: 8298524Abstract: Use of IL-31 agonists, including IL-31, are used to treat agonists are used to treat asthma, airway hyper-responsiveness or allergic rhinitis. The method comprise inhibiting, reducing, limiting or minimizing production of proinflammatory cytokines and include administration of the IL-31 agonist during sensitization or challenge resulting in the asthma, airway hyper-responsiveness or allergic rhinitis state.Type: GrantFiled: August 23, 2011Date of Patent: October 30, 2012Assignee: ZymoGenetics, Inc.Inventors: Janine M. Bilsborough, Eric M. Chadwick, Sherri L. Mudri
-
Patent number: 8227579Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17, IL-23 via it's p19 subunit or both IL-17 and IL-23 (via p19). IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.Type: GrantFiled: August 27, 2010Date of Patent: July 24, 2012Assignee: ZymoGenetics, Inc.Inventors: Katherine E. Lewis, Scott R. Presnell, James W. West, Robert Mabry, Brent Meengs, Steven D. Levin
-
Patent number: 8124065Abstract: The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-? at the amino acid sequence level. The receptor for this protein family is a class II cytokine receptor. The present invention includes methods of reducing viral infections and increasing monocyte counts. The present invention also includes antibodies to the zcyto20 polypeptides, and methods of producing the polynucleotides and polypeptides.Type: GrantFiled: February 15, 2011Date of Patent: February 28, 2012Assignee: ZymoGenetics, Inc.Inventors: Paul O. Sheppard, Brian A. Fox, Kevin M. Klucher, David W. Taft, Wayne Kindsvogel
-
Patent number: 8124378Abstract: The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.Type: GrantFiled: April 8, 2010Date of Patent: February 28, 2012Assignee: ZymoGenetics, Inc.Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Jane A. Gross, Angela K. Hammond, Rolf E. Kuestner
-
Patent number: 8105590Abstract: Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.Type: GrantFiled: March 30, 2011Date of Patent: January 31, 2012Assignee: ZymoGenetics, Inc.Inventors: Yue Yao, Janine Bilsborough
-
Patent number: 8105591Abstract: Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.Type: GrantFiled: March 30, 2011Date of Patent: January 31, 2012Assignee: ZymoGenetics, Inc.Inventors: Yue Yao, Janine Bilsborough
-
Patent number: 8101183Abstract: The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention provides the hybridomas that generate the monoclonal antibodies and the amino acid sequences of the variable regions of the monoclonal antibodies and chimeric antibodies comprising the amino acid sequences of the light and heavy chain variable regions.Type: GrantFiled: September 4, 2007Date of Patent: January 24, 2012Assignee: ZymoGentics, Inc.Inventors: Anthony W. Siadak, Shirley Rene
-
Patent number: 8029775Abstract: Use of IL-31 agonists, including IL-31, are used to treat agonists are used to treat asthma, airway hyper-responsiveness or allergic rhinitis. The method comprise inhibiting, reducing, limiting or minimizing production of proinflammatory cytokines and include administration of the IL-31 agonist during sensitization or challenge resulting in the asthma, airway hyper-responsiveness or allergic rhinitis state.Type: GrantFiled: August 26, 2010Date of Patent: October 4, 2011Assignee: ZymoGenetics, Inc.Inventors: Janine M. Bilsborough, Eric M. Chadwick, Sherri L. Mudri
-
Patent number: 8017122Abstract: The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.Type: GrantFiled: April 8, 2009Date of Patent: September 13, 2011Assignee: ZymoGenetics, Inc.Inventors: Anthony W. Siadak, Janine Bilsborough, Shirley Rene
-
Patent number: 8013124Abstract: The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.Type: GrantFiled: August 18, 2008Date of Patent: September 6, 2011Assignee: ZymoGenetics, Inc.Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Angela K. Hammond, Julia E. Novak
-
Patent number: 7968315Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of IL-29 are described. The vectors utilize the IL-29 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Also included are methods of producing, purifying and pegylating an IL-29 polypeptide.Type: GrantFiled: February 5, 2010Date of Patent: June 28, 2011Assignee: ZymoGenetics, Inc.Inventors: Bruce L. Zamost, Robert M. Dedinsky
-
Patent number: 7919595Abstract: The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-? at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides.Type: GrantFiled: September 30, 2010Date of Patent: April 5, 2011Assignee: ZymoGenetics, Inc.Inventors: Paul O. Sheppard, Scott R. Presnell, Brian A. Fox, Teresa Gilbert, Betty A. Haldeman, Francis J. Grant
-
Patent number: 7910313Abstract: The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-? at the amino acid sequence level. The receptor for this protein family is a class II cytokine receptor. The present invention includes methods of reducing viral infections and increasing monocyte counts. The present invention also includes antibodies to the zcyto20 polypeptides, and methods of producing the polynucleotides and polypeptides.Type: GrantFiled: September 24, 2010Date of Patent: March 22, 2011Assignee: ZymoGenetics, Inc.Inventors: Paul O. Sheppard, Brian A. Fox, Kevin M. Klucher, David W. Taft, Wayne R. Kindsvogel
-
Patent number: 7833520Abstract: The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-? at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides.Type: GrantFiled: November 30, 2009Date of Patent: November 16, 2010Assignee: ZymoGenetics, LLCInventors: Paul O. Sheppard, Scott R. Presnell, Brian A. Fox, Teresa Gilbert, Betty A. Haldeman, Francis J. Grant
-
Patent number: 7829076Abstract: The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-? at the amino acid sequence level. The receptor for this protein family is a class II cytokine receptor. The present invention includes methods of reducing viral infections and increasing monocyte counts. The present invention also includes antibodies to the zcyto20 polypeptides, and methods of producing the polynucleotides and polypeptides.Type: GrantFiled: December 3, 2009Date of Patent: November 9, 2010Assignee: ZymoGenetics, LLCInventors: Paul O. Sheppard, Brian A. Fox, Kevin M. Klucher, David W. Taft, Wayne Kindsvogel
-
Patent number: 7786075Abstract: Methods for treating patients with cancer and autoimmune disorders using IL-28 and IL-29 molecules. The IL-28 and IL-29 molecules include polypeptides that have homology to the human IL-28 or IL-29 polypeptide sequence and proteins fused to a polypeptide with IL-28 and IL-29 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer and/or autoimmune therapeutics.Type: GrantFiled: February 12, 2008Date of Patent: August 31, 2010Assignee: ZymoGenetics, LLCInventors: Sean Doyle, Kevin M. Klucher, Pallavur V. Sivakumar, Wayne R. Kindsvogel, Chung Chan
-
Patent number: 7759092Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of IL-29 are described. The vectors utilize the IL-29 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Also included are methods of producing, purifying and pegylating an IL-29 polypeptide.Type: GrantFiled: August 7, 2009Date of Patent: July 20, 2010Assignee: ZymoGenetics, LLCInventors: Bruce L. Zamost, Robert M. Dedinsky
-
Patent number: 7727518Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: GrantFiled: March 6, 2008Date of Patent: June 1, 2010Assignee: ZymoGenetics, LLCInventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski